Literature DB >> 19399798

Liver biopsy findings in chronic hepatitis B.

Haresh Mani1, David E Kleiner.   

Abstract

Liver biopsy plays a central role in treatment algorithms in patients with hepatitis B and remains the gold standard for evaluating hepatic pathology. The pathology of hepatitis B is diverse and reflects the natural history of infection. An acute hepatitic pattern with lobular disarray is seen in acute infection, during acute flares of disease, and with acute hepatitis D superinfection. In chronic hepatitis B, inflammation is less pronounced in the immune-tolerant phase and is prominent during immune-mediated viral clearance. Active inflammation appears to be the driving force for development of fibrosis. Inflammatory grades and fibrosis stage are assigned as is done for hepatitis C. Although current management guidelines recommend liver biopsies only in select patients based on age, viral levels, and hepatitis B e antigen status, these clinical and biochemical parameters do not show consistent correlations with liver histology. Liver biopsy also helps identify preneoplastic lesions including large cell and small cell change. Unlike in other causes of chronic hepatitis, immunostains are widely used and can help determine the phase of infection. Liver biopsies can also identify additional pathology that may contribute to liver disease such as steatohepatitis, iron overload, autoimmune hepatitis, and drug-induced injury. Thus, liver biopsy can play an important role in staging and grading chronic hepatitis B and should be more widely used in assessing the need for therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19399798     DOI: 10.1002/hep.22930

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  46 in total

Review 1.  Evolution of the liver biopsy and its future.

Authors:  Dhanpat Jain; Richard Torres; Romulo Celli; Jeremy Koelmel; Georgia Charkoftaki; Vasilis Vasiliou
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

2.  Alteration of interferon-α/β receptors in chronic hepatitis B patients.

Authors:  Fanli Meng; Jiefei Wang; Jian Ge; Xiaopeng Fan; Bing Wang; Liyan Han; Tatiana Kisseleva; YongHan Paik; David A Brenner; Kai Wang
Journal:  J Clin Immunol       Date:  2011-03-29       Impact factor: 8.317

Review 3.  Therapy for alcoholic liver disease.

Authors:  Maryconi M Jaurigue; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

4.  Core antigen expression is associated with hepatic necroinflammation in e antigen-negative chronic hepatitis B patients with low DNA loads.

Authors:  Yi-Hsiang Huang; Hung-Hsu Hung; Che-Chang Chan; Chiung-Ru Lai; Chi-Jen Chu; Teh-Ia Huo; Pui-Ching Lee; Chien-Wei Su; Keng-Hsin Lan; Hui-Chun Huang; I-Cheng Lee; Han-Chieh Lin; Shou-Dong Lee
Journal:  Clin Vaccine Immunol       Date:  2010-04-28

5.  Immune tolerant hepatitis B: a clinical dilemma.

Authors:  Tram T Tran
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-08

Review 6.  Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B.

Authors:  Masaru Enomoto; Hiroyasu Morikawa; Akihiro Tamori; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

7.  Polystyrene microsphere-ferritin conjugates: a robust phantom for correlation of relaxivity and size distribution.

Authors:  Preeti A Sukerkar; Uzma G Rezvi; Keith W Macrenaris; Pinal C Patel; John C Wood; Thomas J Meade
Journal:  Magn Reson Med       Date:  2010-10-28       Impact factor: 4.668

8.  Hepatitis B Virus Polymerase Localizes to the Mitochondria, and Its Terminal Protein Domain Contains the Mitochondrial Targeting Signal.

Authors:  Nuruddin Unchwaniwala; Nathan M Sherer; Daniel D Loeb
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

Review 9.  Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools.

Authors:  Yan Wang; Jin-Lin Hou
Journal:  Hepatol Int       Date:  2016-01-07       Impact factor: 6.047

Review 10.  Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection.

Authors:  Da-Wu Zeng; Jing Dong; Yu-Rui Liu; Jia-Ji Jiang; Yue-Yong Zhu
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.